Munich, November 1st, 2022
stradoo is excited about supporting the OPTIMA consortium improving patient outcomes and making healthcare systems more efficient.
Optimal treatment for patients with solid tumors in Europe through Artificial Intelligence (in short: OPTIMA) is a collaborative European oncology research project funded by the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
stradoo – a globally acting strategy consulting and advisory firm focusing exclusively on the Life Science industry – is currently supporting the IMI initiative with a project to build a “Sustainability Strategy for OPTIMA” and to identify potential pathways and business models for the time after the grant period. stradoo has already collected comparable experience in previous IMI projects and has successfully supported PIONEER and HARMONY as well as other RWE projects and scientific partners (various patient registries, etc.) in the past.
Munich, June 1st, 2021
stradoo® has been honored with the prestigious Pharma Tech Outlook Award “Top 10 Pharma Marketing Consultancy”. As a life sciences focused strategy consulting firm headquartered in Germany and operating globally, stradoo has been commended with this award and holds this title with great pride and honor.
Pharma Tech Outlook is a leading monthly publication that has been a pioneer in bringing forth key trends in the pharmaceuticals industry, real world solutions, and the implications for pharma marketing. The magazine is based on a unique learn-from-peers approach providing decision markers a platform to constantly sharing their experience, wisdom and thought leadership among each other.
Annually, Pharma Tech Outlook compiles a list of “the most commendable pharmaceutical marketing consultancies” based on the recommendations of a distinguished panel of prominent CEOs, CIOs, VCs, analysts, and the editorial board of Pharma Tech Outlook. Following an evaluation, the resulting list comprises “10 companies that are at the forefront of providing Pharma Marketing consulting services and transforming businesses” in Europe.
stradoo® has been recognized for this award due to its distinguishing core principles of providing consulting services to its clients in the pharmaceutical and life sciences industry: combining deep industry knowledge and expertise with historically proven innovative project methodologies, stradoo fosters long-term success and operational excellence with its clients.
Alongside years of experience and high customer satisfaction, this reward supports stradoo’s success as a uniquely positioned consultancy in the pharmaceutical and life sciences industry.
Munich, September 12th, 2018
GHO Capital, the European specialist investor in healthcare, has recently completed the acquisition of Linimed Gruppe, a leading provider of outpatient intensive care services across Germany, from Vitruvian Partners.
stradoo® supported GHO Capital as commercial and strategic advisor on the transaction. On the back of deep industry experience and a wide range network in the care industry stradoo was able to provide GHO Capital with valuable insights into the company and the transaction.
Headquartered in Jena, Linimed Gruppe is one of the largest providers of outpatient intensive care in Germany, operating through 44 clinical care locations. The Com-pany is the leading provider of outpatient intensive care in community settings, enabling efficient care to the highest quality standards. The core service offering of Lin-imed consists of 24/7 intensive care in specialised community centres to patients with severe health problems (including neurological and neuromuscular diseases, ob-structive respiratory diseases, restrictive thoracic diseases, premature birth, as well as other conditions).
The Company has approximately 1,100 employees and operates a portfolio of modern and functional facilities positioned mostly in Eastern and Central Germany. The high quality of Linimed facilities, coupled with high standards of care, has contrib-uted to the attainment of best-in-class quality ratings.
The outpatient intensive care market in Germany currently consists of approximately 20,000 patients. Over the past five years, community care has risen from 12% to 31% of outpatient intensive care provision. Over the next five years, the overall number of patients is expected to increase to 26,000 with community care growing at an esti-mated compound annual growth rate of 16%.
Alan MacKay, Executive Partner & Founder of GHO Capital, commented: “At GHO we look to partner with the best healthcare businesses in Europe – working with stradoo® gave GHO valuable insights for the Linimed Gruppe transaction such that we were able to confirm our preliminary assessment of Linimed Gruppe as best in class.”